These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 32952)
1. Aetiology and natural history of Parkinson's disease. Pearce JM Br Med J; 1978 Dec; 2(6153):1664-6. PubMed ID: 32952 [No Abstract] [Full Text] [Related]
7. [Will the mystery of Parkinson's disease be resolved?]. Lyytinen J; Kaakkola S Duodecim; 2005; 121(3):275-84. PubMed ID: 15787285 [No Abstract] [Full Text] [Related]
8. Parkinson's disease and levodopa. A five-year follow-up and review. Markham CH; Treciokas LJ; Diamond SG West J Med; 1974 Sep; 121(3):188-206. PubMed ID: 4606887 [No Abstract] [Full Text] [Related]
9. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness. Hornykiewicz O Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366 [TBL] [Abstract][Full Text] [Related]
10. Current views on Parkinson's disease. Calne DB Can J Neurol Sci; 1983 Feb; 10(1):11-5. PubMed ID: 6132677 [TBL] [Abstract][Full Text] [Related]
12. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role? Agid Y; Graybiel AM; Ruberg M; Hirsch E; Blin J; Dubois B; Javoy-Agid F Adv Neurol; 1990; 53():83-100. PubMed ID: 1978522 [No Abstract] [Full Text] [Related]
13. [What is the Best Initial Treatment for Parkinson's Disease? New Clinical Practice Guideline and My Personal Opinion]. Takeda A Brain Nerve; 2019 Aug; 71(8):857-867. PubMed ID: 31346142 [TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease. Marsden CD Postgrad Med J; 1992 Jul; 68(801):538-43. PubMed ID: 1437950 [No Abstract] [Full Text] [Related]
15. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. Kempster PA; Gibb WR; Stern GM; Lees AJ J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):72-6. PubMed ID: 2709038 [TBL] [Abstract][Full Text] [Related]
16. Potential nondopaminergic drugs for Parkinson's disease. Silverdale MA; Fox SH; Crossman AR; Brotchie JM Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686 [No Abstract] [Full Text] [Related]
17. The use of PET in Parkinson's disease. Shinotoh H; Calne DB Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856 [TBL] [Abstract][Full Text] [Related]
18. The nigrostriatal system in Parkinson's disease. Graybiel AM; Hirsch EC; Agid Y Adv Neurol; 1990; 53():17-29. PubMed ID: 1978514 [TBL] [Abstract][Full Text] [Related]
19. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease. Melamed E Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303 [No Abstract] [Full Text] [Related]